17-43093819-A-G
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_007294.4(BRCA1):āc.1712T>Cā(p.Ile571Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000192 in 1,613,480 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_007294.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152062Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 250738Hom.: 0 AF XY: 0.00000738 AC XY: 1AN XY: 135572
GnomAD4 exome AF: 0.0000198 AC: 29AN: 1461300Hom.: 0 Cov.: 34 AF XY: 0.0000206 AC XY: 15AN XY: 726992
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152180Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74380
ClinVar
Submissions by phenotype
not provided Uncertain:4
- -
- -
Observed in individuals with breast or prostate cancer (PMID: 15726418, 20104584, 22516946, 30400234); In silico analysis indicates that this missense variant does not alter protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); Also known as 1831T>C; This variant is associated with the following publications: (PMID: 16267036, 20104584, 15726418, 15235020, 22516946, 15385441, 30400234, 26295337, 31959133, 15343273) -
The BRCA1 c.1712T>C (p.Ile571Thr) variant has been reported in individuals with breast and/or ovarian cancer (PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared)), 30400234 (2018), 20104584 (2010), 15726418 (2005)), prostate cancer (PMID: 22516946 (2012)), and glioblastoma (PMID: 31959133 (2020)). This variant has also been observed in reportedly healthy individuals (PMID: 15726418 (2005)). The frequency of this variant in the general population, 0.000012 (3/250738 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:3
- -
- -
- -
Hereditary cancer-predisposing syndrome Benign:3
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). -
not specified Uncertain:1
Variant summary: BRCA1 c.1712T>C (p.Ile571Thr) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 250930 control chromosomes (gnomAD and McKean-Cowdin_2005). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1712T>C has been reported in the literature in individuals affected with breast, ovarian, and prostate cancers without strong evidence for causality (e.g. Judkins_2005, McKean-Cowdin_2005, Borg_2010, Leongamornlert_2012, Diaz-Zabala_2018). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 16267036, 15385441, 20104584, 15235020, 21520273, 22516946, 15726418, 25348012, 30400234). ClinVar contains an entry for this variant (Variation ID: 54330). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Breast and/or ovarian cancer Uncertain:1
- -
Hereditary breast ovarian cancer syndrome Uncertain:1
This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 571 of the BRCA1 protein (p.Ile571Thr). This variant is present in population databases (rs80357159, gnomAD 0.003%). This missense change has been observed in individual(s) with breast and/or ovarian cancer or prostate cancer (PMID: 15726418, 20104584, 21520273, 22516946). ClinVar contains an entry for this variant (Variation ID: 54330). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt BRCA1 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at